Inhibitory Antibodies

A monoclonal antibody is secreted by a single B lymphocyte clone which can only produce a kind of proprietary antibody against an antigen-determining cluster, and has the characteristics of single biological activity and particular specificity of binding with antigen.

The active sites of monoclonal antibody drugs involve a variety of tumor-related signaling pathways and targets. For example, the most common targets are epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor -2 (her-2 /neu, or egfr-2). Besides, there is a group of targets that are getting a lot of attention called “immune checkpoints”.

After the activation of immune cells that regulate the anti-tumor immune response, a variety of highly expressed receptors on the surface of immune cells bind to the highly expressed ligands on the surface of tumor cells to reduce the strength of the immune response, thus down-regulating the intensity of tumor-related immune response. These immunoregulatory sites are known as immune checkpoints. Currently, the most widely studied immune checkpoints are PD-1, PD-L1, and CTLA-4.

Targetmol provides xnum monoclonal antibody drugs, including the above immune checkpoint inhibitors and other types of targeted antibody inhibitors, for scientific research only.

Cat. No.	Product name	CAS No.	Purity	Chemical Structure
T9923	Nimotuzumab	828933-51-3	95.00%
T9923	Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).
T64086	PD-1/PD-L1-IN-20	2159138-01-7	98%
T64086	PD-1/PD-L1-IN-20 is a small molecule inhibitor of PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-20 blocks the PD-1/PD-L1 interaction (IC50: 5.29 nM). PD-...
T77845	Ozuriftamab	2460399-44-2	98%	Ozuriftamab
T77845	Ozuriftamab, a naked (human IgG1 kappa) antibody targeting the (receptor tyrosine kinase-like orphan receptor 2 (ROR2)), serves as a precursor for the synthesis ...			Ozuriftamab
T77905	Vobramitamab	2490556-50-6	98%	Vobramitamab
T77905	Vobramitamab, a humanized B7-H3 monoclonal antibody (mAb), is conjugated to the prodrug seco-DUBA through a cleavable linker, creating the antibody-drug conjugat...			Vobramitamab
T77906	Briobacept	869881-54-9	98%	Briobacept
T77906	Briobacept (BR 3FC), a selective human monoclonal antibody, targets BLyS (BAFF) to induce B-cell apoptosis and is a recombinant glycoprotein comprising two BLyS ...			Briobacept
T77911	Cantuzumab	1204740-23-7	98%	Cantuzumab
T77911	Cantuzumab, a monoclonal antibody, binds to the CanAg antigen and is commonly conjugated with various cytotoxic agents to form antibody-drug conjugates (ADCs), i...			Cantuzumab
T78241	Asfotase alfa	1174277-80-5	98%	Asfotase alfa
T78241	Asfotase alfa (ENB-0040), a bone-targeted genetically engineered glycoprotein, enhances survival, bone mineralization, and growth while preventing mineralization...			Asfotase alfa
T78242	Human IgG1 kappa, Isotype Control		98%	Human IgG1 kappa, Isotype Control
T78242	Human IgG1 kappa Isotype Control is a human monoclonal antibody serving as an isotype control specifically for human IgG1κ antibodies [1].			Human IgG1 kappa, Isotype Control
T78243	Human IgG2 kappa, Isotype Control		98%	Human IgG2 kappa, Isotype Control
T78243	Human IgG2 kappa Isotype Control is a monoclonal antibody serving as an isotype control specific to human IgG2κ antibodies [1].			Human IgG2 kappa, Isotype Control
T78244	Human IgG4 kappa, Isotype Control		98%	Human IgG4 kappa, Isotype Control
T78244	Human IgG4 kappa Isotype Control is a monoclonal antibody serving as an isotype control for the human IgG4κ antibody [1].			Human IgG4 kappa, Isotype Control
T78245	Batoclimab	2187430-05-1	98%	Batoclimab
T78245	Batoclimab, a human anti-FcRn monoclonal antibody, is utilized in the study of IgG-mediated autoimmune diseases [1].			Batoclimab
T78246	Lemzoparlimab	2377483-71-9	98%	Lemzoparlimab
T78246	Lemzoparlimab (TJ011133; TJC4), a humanized anti-CD47 IgG4 antibody, exhibits potent antitumor activity [1].			Lemzoparlimab
T78247	Ieramilimab		98%	Ieramilimab
T78247	Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that targets LAG-3, disrupting its interaction with MHC-II molecules [1].			Ieramilimab
T78248	Nesvacumab	1296818-77-3	98%	Nesvacumab
T78248	Nesvacumab, a fully human immunoglobulin G1 (IgG1) monoclonal antibody, selectively binds to and inactivates Angiopoietin-2 (Ang2), the ligand for the Tie2 recep...			Nesvacumab
T78249	Nipocalimab	2211985-36-1	98%	Nipocalimab
T78249	Nipocalimab (M281), a fully human, recombinant, aglycosylated IgG1 monoclonal antibody, exhibits high-affinity binding to the Fc receptor (FcRn) at both endosoma...			Nipocalimab
T78250	Selicrelumab	1622140-49-1	98%	Selicrelumab
T78250	Selicrelumab, an agonist CD40 antibody, modifies the tumor microenvironment and is utilized in pancreatic cancer research and neoadjuvant studies [1].			Selicrelumab
T78251	Sotigalimab	2305607-45-6	98%	Sotigalimab
T78251	Sotigalimab, a CD40 agonistic monoclonal antibody, is utilized in research targeting metastatic pancreatic adenocarcinoma [1].			Sotigalimab
T78252	Bebtelovimab	2578319-11-4	98%	Bebtelovimab
T78252	Bebtelovimab is a humanized IgG1-λ2 antibody specifically targeting SARS-CoV-2 and has demonstrated potent neutralization against its variants, exhibiting mild-t...			Bebtelovimab
T78253	Faricimab	1607793-29-2	98%	Faricimab
T78253	Faricimab, a bispecific antibody, simultaneously targets angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A), and is utilized in research on diabeti...			Faricimab
T78254	Anti-Mouse CD209b Antibody (22D1)		98%	Anti-Mouse CD209b Antibody (22D1)
T78254	Anti-Mouse CD209b Antibody is an IgG1 inhibitor targeting mouse CD209b, sourced from the Armenian Hamster.			Anti-Mouse CD209b Antibody (22D1)